Transforming Personalised Acute Myeloid Leukaemia Therapy through an Integrative European Multi-Centre Multi-Omics Network
| Reference number | |
| Coordinator | Karolinska Institutet |
| Funding from Vinnova | SEK 2 967 777 |
| Project duration | January 2026 - December 2028 |
| Status | Ongoing |
| Venture | European partnership for Personalised Medicine |
| Call | International collaboration in pharmacogenomics in personalised medicine |
Purpose and goal
TRANS-AML-EU aims to improve AML precision therapy by establishing a GDPR-compliant federated European multi-omics and drug-response resource (>1,000 cases) and deriving Data-Driven Hallmarks (DDHMs) that enable patient-tailored treatment selection. We will also develop Translational Tool Boxes (TTBs) for clinical deployment.
Expected effects and result
We will deliver an open AML Hallmark Atlas, validated DDHM-based prediction models, and 3–5 TTB dossiers (assay + algorithm + SOP) ready for clinical workflows. Expected impact includes improved patient stratification, more accurate treatment selection, and a scalable blueprint for privacy-preserving federated analysis and implementation across countries.
Planned approach and implementation
Work is organized in three steps: (1) harmonize and federate multi-omics, clinical and ex vivo drug-response data and define DDHMs using AI models; (2) distill actionable DDHMs into TTBs with minimal biomarker panels, locked algorithms and SOPs; (3) multicentre validation and piloting of TTBs, plus long-term infrastructure and implementation support.